PT-141

PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist developed originally as a metabolite of Melanotan II. It was the first centrally-acting agent approved for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi by Palatin Technologies/AMAG Pharmaceuticals and approved by the FDA in 2019. Unlike phosphodiesterase inhibitors (sildenafil, tadalafil) that act on peripheral vascular mechanisms, PT-141 acts directly on melanocortin-4 receptors (MC4R) in the hypothalamus to enhance sexual desire and arousal through central nervous system pathways.

The peptide differs from its parent compound Melanotan II by the removal of the amino terminal and C-terminal amide, producing a metabolite that retains MC4R activity for sexual function while substantially reducing MC1R-mediated tanning effects. Its approval represented a paradigm shift in sexual medicine — from treating the mechanical aspects of sexual response to targeting the neural circuits underlying desire itself.

PT-141 activates melanocortin-4 receptors (MC4R) in the medial preoptic area and paraventricular nucleus of the hypothalamus, brain regions that integrate sexual arousal, motivation, and autonomic responses. MC4R activation in these areas stimulates downstream oxytocin and dopamine release in mesolimbic reward circuits, enhancing sexual desire and emotional arousal rather than directly affecting genital vasodilation.

The melanocortin system serves as a central integrator of metabolic and reproductive signals — MC4R receives input from leptin signaling (nutritional status), circadian systems, and social cues. PT-141 activates this receptor independent of these upstream inputs, which is why it can enhance desire even in contexts where endogenous melanocortin tone is low. The cyclic structure of PT-141 confers selectivity and metabolic stability. While it has affinity for multiple melanocortin receptor subtypes (MC1R through MC5R), its functional effects are mediated primarily through MC4R, as demonstrated by the loss of sexual response effects in MC4R knockout animal models.